bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure 6 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Authors: Das Anirban , Fernandez Nicholas R. , Levine Adrian , Bianchi Vanessa , Stengs Lucie K. , Chung Jiil , Negm Logine , Dimayacyac Jose Rafael , Chang Yuan , Nobre Liana , Ercan Ayse B. , Sanchez-Ramirez Santiago , Sudhaman Sumedha , Edwards Melissa , Larouche Valerie , Samuel David , Van Damme An , Gass David , Ziegler David S. , Bielack Stefan S. , Koschmann Carl , Zelcer Shayna , Yalon-Oren Michal , Campino Gadi Abede , Sarosiek Tomasz , Nichols Kim E. , Loret De Mola Rebecca , Bielamowicz Kevin , Sabel Magnus , Frojd Charlotta A. , Wood Matthew D. , Glover Jason M. , Lee Yi-Yen , Vanan Magimairajan , Adamski Jenny K. , Perreault Sebastien , Chamdine Omar , Hjort Magnus Aasved , Zapotocky Michal , Carceller Fernando , Wright Erin , Fedorakova Ivana , Lossos Alexander , Tanaka Ryuma , Osborn Michael , Blumenthal Deborah T. , Aronson Melyssa , Bartels Ute , Huang Annie , Ramaswamy Vijay , Malkin David , Shlien Adam , Villani Anita , Dirks Peter B. , Pugh Trevor J. , Getz Gad , Maruvka Yosef E. , Tsang Derek S. , Ertl-Wagner Birgit , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A. , Tabori Uri
Published: February 2024

Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
Figure 5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Authors: Das Anirban , Fernandez Nicholas R. , Levine Adrian , Bianchi Vanessa , Stengs Lucie K. , Chung Jiil , Negm Logine , Dimayacyac Jose Rafael , Chang Yuan , Nobre Liana , Ercan Ayse B. , Sanchez-Ramirez Santiago , Sudhaman Sumedha , Edwards Melissa , Larouche Valerie , Samuel David , Van Damme An , Gass David , Ziegler David S. , Bielack Stefan S. , Koschmann Carl , Zelcer Shayna , Yalon-Oren Michal , Campino Gadi Abede , Sarosiek Tomasz , Nichols Kim E. , Loret De Mola Rebecca , Bielamowicz Kevin , Sabel Magnus , Frojd Charlotta A. , Wood Matthew D. , Glover Jason M. , Lee Yi-Yen , Vanan Magimairajan , Adamski Jenny K. , Perreault Sebastien , Chamdine Omar , Hjort Magnus Aasved , Zapotocky Michal , Carceller Fernando , Wright Erin , Fedorakova Ivana , Lossos Alexander , Tanaka Ryuma , Osborn Michael , Blumenthal Deborah T. , Aronson Melyssa , Bartels Ute , Huang Annie , Ramaswamy Vijay , Malkin David , Shlien Adam , Villani Anita , Dirks Peter B. , Pugh Trevor J. , Getz Gad , Maruvka Yosef E. , Tsang Derek S. , Ertl-Wagner Birgit , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A. , Tabori Uri
Published: February 2024

Impact of radiotherapy. A, Patient progressing on nivolumab received reirradiation, following which further progression prompted the addition of ipilimumab. This was followed by radiologic flare, and continued treatment with supportive care led to delayed response. B, Impact of reirradiation on survival. C, Impact of additional reirradiation (RT) in patients who received nivolumab and ipilimumab. D, Relative contribution of the radiation-induced indel signature (ID8) in RRD-HGG and controls from the GLASS cohort (Methods). E, Paired analysis of the relative contribution of ID8 before (at diagnosis) and after the second progression (post primary radiation, and then immunotherapy at first progression) in five patients.
Figure 4 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Authors: Das Anirban , Fernandez Nicholas R. , Levine Adrian , Bianchi Vanessa , Stengs Lucie K. , Chung Jiil , Negm Logine , Dimayacyac Jose Rafael , Chang Yuan , Nobre Liana , Ercan Ayse B. , Sanchez-Ramirez Santiago , Sudhaman Sumedha , Edwards Melissa , Larouche Valerie , Samuel David , Van Damme An , Gass David , Ziegler David S. , Bielack Stefan S. , Koschmann Carl , Zelcer Shayna , Yalon-Oren Michal , Campino Gadi Abede , Sarosiek Tomasz , Nichols Kim E. , Loret De Mola Rebecca , Bielamowicz Kevin , Sabel Magnus , Frojd Charlotta A. , Wood Matthew D. , Glover Jason M. , Lee Yi-Yen , Vanan Magimairajan , Adamski Jenny K. , Perreault Sebastien , Chamdine Omar , Hjort Magnus Aasved , Zapotocky Michal , Carceller Fernando , Wright Erin , Fedorakova Ivana , Lossos Alexander , Tanaka Ryuma , Osborn Michael , Blumenthal Deborah T. , Aronson Melyssa , Bartels Ute , Huang Annie , Ramaswamy Vijay , Malkin David , Shlien Adam , Villani Anita , Dirks Peter B. , Pugh Trevor J. , Getz Gad , Maruvka Yosef E. , Tsang Derek S. , Ertl-Wagner Birgit , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A. , Tabori Uri
Published: February 2024

Patients treated with nivolumab and trametinib (n = 5). A, Objective responses in bifocal glioblastoma progressing on nivolumab. B, Swimmer's plot summarizing events in each patient. C, The patient progressing at primary and distant sites on nivolumab had complete response on being simultaneously treated with radiation and addition of trametinib to nivolumab. T-cell receptor (TCR) clonotype analysis shows an initial increase in TCRB after starting on nivolumab, and invigoration of response at salvage treatment postprogression. This was observed both in terms of increased absolute clonal counts after adding trametinib, as well as clonal selection, plausibly for more tumor-specific TCR clones (as shown by the colored bars), as this correlated with the response seen in radiology. MEK-i, MEK inhibitor.
Supplementary Table 9 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Myeloid network.

Regulatory network for PDAC-associated myeloid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Figure 3 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Authors: Das Anirban , Fernandez Nicholas R. , Levine Adrian , Bianchi Vanessa , Stengs Lucie K. , Chung Jiil , Negm Logine , Dimayacyac Jose Rafael , Chang Yuan , Nobre Liana , Ercan Ayse B. , Sanchez-Ramirez Santiago , Sudhaman Sumedha , Edwards Melissa , Larouche Valerie , Samuel David , Van Damme An , Gass David , Ziegler David S. , Bielack Stefan S. , Koschmann Carl , Zelcer Shayna , Yalon-Oren Michal , Campino Gadi Abede , Sarosiek Tomasz , Nichols Kim E. , Loret De Mola Rebecca , Bielamowicz Kevin , Sabel Magnus , Frojd Charlotta A. , Wood Matthew D. , Glover Jason M. , Lee Yi-Yen , Vanan Magimairajan , Adamski Jenny K. , Perreault Sebastien , Chamdine Omar , Hjort Magnus Aasved , Zapotocky Michal , Carceller Fernando , Wright Erin , Fedorakova Ivana , Lossos Alexander , Tanaka Ryuma , Osborn Michael , Blumenthal Deborah T. , Aronson Melyssa , Bartels Ute , Huang Annie , Ramaswamy Vijay , Malkin David , Shlien Adam , Villani Anita , Dirks Peter B. , Pugh Trevor J. , Getz Gad , Maruvka Yosef E. , Tsang Derek S. , Ertl-Wagner Birgit , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A. , Tabori Uri
Published: February 2024

Patients receiving dual-checkpoint inhibition with ipilimumab and anti–PD-1 after failing ICI monotherapy (n = 24). A, Swimmer's plot for each patient, showing the best documented radiologic response at any time during treatment. Inset, representative radiologic image showing response to dual-checkpoint inhibition. B, Progression-free (PFS2) and overall survival (OS2). C, Normalized CTLA4 expression counts generated using NanoString platform (Methods) for in-house non-RRD, nonmalignant brain controls, and at different time points for RRD-HGG. D, Paired analysis of normalized CTLA4 expression counts before and after anti–PD-1 therapy for the same patient. E, Toxicities (≥CTCAE grade 3) observed in CMMRD and Lynch syndrome patients on dual ICI.
Figure 2 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Authors: Das Anirban , Fernandez Nicholas R. , Levine Adrian , Bianchi Vanessa , Stengs Lucie K. , Chung Jiil , Negm Logine , Dimayacyac Jose Rafael , Chang Yuan , Nobre Liana , Ercan Ayse B. , Sanchez-Ramirez Santiago , Sudhaman Sumedha , Edwards Melissa , Larouche Valerie , Samuel David , Van Damme An , Gass David , Ziegler David S. , Bielack Stefan S. , Koschmann Carl , Zelcer Shayna , Yalon-Oren Michal , Campino Gadi Abede , Sarosiek Tomasz , Nichols Kim E. , Loret De Mola Rebecca , Bielamowicz Kevin , Sabel Magnus , Frojd Charlotta A. , Wood Matthew D. , Glover Jason M. , Lee Yi-Yen , Vanan Magimairajan , Adamski Jenny K. , Perreault Sebastien , Chamdine Omar , Hjort Magnus Aasved , Zapotocky Michal , Carceller Fernando , Wright Erin , Fedorakova Ivana , Lossos Alexander , Tanaka Ryuma , Osborn Michael , Blumenthal Deborah T. , Aronson Melyssa , Bartels Ute , Huang Annie , Ramaswamy Vijay , Malkin David , Shlien Adam , Villani Anita , Dirks Peter B. , Pugh Trevor J. , Getz Gad , Maruvka Yosef E. , Tsang Derek S. , Ertl-Wagner Birgit , Hawkins Cynthia , Bouffet Eric , Morgenstern Daniel A. , Tabori Uri
Published: February 2024

Genomic features of patients with RRD-HGG treated with salvage therapies (n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
Supplementary Table 7 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Fibroblast network.

Regulatory network for PDAC-associated fibroblasts, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Supplementary Table 5 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Endothelial network.

Regulatory network for PDAC-associated endothelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).
Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

RLY-2608 biochemical inhibition with liposome substrates
Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

Time-dependence of biochemical inhibition and mutant selectivity of RLY-2608
Supplementary Table 10 - 13 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Supplementary Table 10: Antibodies for IHC and IF.

Overview of antibodies used for stainings in human PDAC or KPC-derived tissues.

Supplementary Table 11: Primer sequences for qRT-PCR.

Primers for qRT-PCR-based quantification of ChIP and mRNA samples.

Supplementary Table 12: Freezer dryer settings for sponge production.

Specific settings for optimal sponge production.

Supplementary Table 13: Explant media composition.

List of reagents used for human PDAC and murine explants.
Supplementary Figure 8 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Single cell analysis of paracrine cascades in KPC PDAC.
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

Body weight changes observed in in vivo models upon treatment with RLY-2608
Supplementary Figure 6 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Abrogation of SHH signaling fuels hypersprouting in human and murine PDAC explants.
Supplementary Figure 5 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

SHH secretion in vitro and ex vivo.
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

Varied levels of PI3Kα-dependency across cell lines
Supplementary Figure 4 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Explant cellular populations throughout culture.
Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

Isoform selectivity of RLY-2608
Supplementary Figure 3 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Explant cellular populations.
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Authors: Varkaris Andreas , Pazolli Ermira , Gunaydin Hakan , Wang Qi , Pierce Levi , Boezio Alessandro A. , Bulku Artemisa , DiPietro Lucian , Fridrich Cary , Frost Adam , Giordanetto Fabrizio , Hamilton Erika P. , Harris Katherine , Holliday Michael , Hunter Tamieka L. , Iskandar Amanda , Ji Yongli , Larivée Alexandre , LaRochelle Jonathan R. , Lescarbeau André , Llambi Fabien , Lormil Brenda , Mader Mary M. , Mar Brenton G. , Martin Iain , McLean Thomas H. , Michelsen Klaus , Pechersky Yakov , Puente-Poushnejad Erika , Raynor Kevin , Rogala Dipali , Samadani Ramin , Schram Alison M. , Shortsleeves Kelley , Swaminathan Sweta , Tajmir Shahein , Tan Gege , Tang Yong , Valverde Roberto , Wehrenberg Bryan , Wilbur Jeremy , Williams Bret R. , Zeng Hongtao , Zhang Hanmo , Walters W. Patrick , Wolf Beni B. , Shaw David E. , Bergstrom Donald A. , Watters James , Fraser James S. , Fortin Pascal D. , Kipp D. Randal
Published: February 2024

Binding kinetics and potency of [2] towards PI3Kα
Supplementary Figure 1 from Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression
Authors: Hasselluhn Marie C. , Decker-Farrell Amanda R. , Vlahos Lukas , Thomas Dafydd H. , Curiel-Garcia Alvaro , Maurer H. Carlo , Wasko Urszula N. , Tomassoni Lorenzo , Sastra Stephen A. , Palermo Carmine F. , Dalton Tanner C. , Ma Alice , Li Fangda , Tolosa Ezequiel J. , Hibshoosh Hanina , Fernandez-Zapico Martin E. , Muir Alexander , Califano Andrea , Olive Kenneth P.
Published: February 2024

Overview of single cell regulatory network analysis.
Supplementary Table S3 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Authors: Sang Wenhua , Zhou Yiduo , Chen Haiyan , Yu Chengxuan , Dai Lisi , Liu Zhongkun , Chen Lang , Fang Yimin , Ma Panpan , Wu Xiangji , Kong Hao , Liao Wenting , Jiang Hong , Qian Junbin , Wang Da , Liu Yun-Hua
Published: February 2024

Supplementary Table S3. Detailed information of reagents and resources used in this study.
Supplementary Table 1 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Nanostring gene signature subsets in the PanCancer Immune panel.
Supplementary Table S2 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Authors: Sang Wenhua , Zhou Yiduo , Chen Haiyan , Yu Chengxuan , Dai Lisi , Liu Zhongkun , Chen Lang , Fang Yimin , Ma Panpan , Wu Xiangji , Kong Hao , Liao Wenting , Jiang Hong , Qian Junbin , Wang Da , Liu Yun-Hua
Published: February 2024

Supplementary Table S2. Detailed information of human pancreatic tissue array.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Authors: Sang Wenhua , Zhou Yiduo , Chen Haiyan , Yu Chengxuan , Dai Lisi , Liu Zhongkun , Chen Lang , Fang Yimin , Ma Panpan , Wu Xiangji , Kong Hao , Liao Wenting , Jiang Hong , Qian Junbin , Wang Da , Liu Yun-Hua
Published: February 2024

Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
Supplementary Figure 7 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Human TNBC single cell RNA sequencing gene correlation and representative mIF
Supplementary Figure 3 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Nanostring and flow cytometry immune profiling analysis
Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Tumor growth curves for tumors with varying MHC-I loss
Supplementary Figure 1 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Antibody HLA specificity and kurtosis parameter
Supplementary Data 1 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Authors: Taylor Brandie C. , Sun Xiaopeng , Gonzalez-Ericsson Paula I. , Sanchez Violeta , Sanders Melinda E. , Wescott Elizabeth C. , Opalenik Susan R. , Hanna Ann , Chou Shu-Ting , Van Kaer Luc , Gomez Henry , Isaacs Claudine , Ballinger Tarah J. , Santa-Maria Cesar A. , Shah Payal D. , Dees Elizabeth C. , Lehmann Brian D. , Abramson Vandana G. , Pietenpol Jennifer A. , Balko Justin M.
Published: February 2024

Nanostring PanCancer Immune Panel data and metadata for experimental conditions.
Supplementary Data Table S8 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Table S8 showing the impact of removal of mutant KRAS in human cancer cell lines in vitro by CRISPR/Cas9 by mining the DepMap database
Supplementary Data Table S7 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Table S7 showing the impact of removal of mutant BRAF in human cancer cell lines in vitro by RNAi by mining the DepMap database
Supplementary Data Table S6 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Table S6 showing the impact of removal of mutant BRAF in human cancer cell lines in vitro by CRISPR/Cas9 by mining the DepMap database
Supplementary Data Table S5 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Table S5 showing the impact of removal of mutant TP53 in human cancer cell lines in vitro by RNAi by mining the DepMap database
Supplementary Data Table S2 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Table S2 showing statistical analysis of differences in the survival of human cancer cells in vitro with or without removal of mutant TP53
Supplementary Data Figure S9 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S9 showing that complete removal of mutant TP53 in Rael-BL cells does not impair survival and proliferation in culture
Supplementary Data Figure S7 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S7 showing that complete removal of mutant TP53 in MDA-MB-231 cells does not impair survival and proliferation in culture
Supplementary Data Figure S6 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S6 showing that removal of mutant TP53 does not impact the chemotherapy responses of diverse human cancer cell lines in culture
Supplementary Data Figure S5 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S5 showing that removal of mutant TP53 has no impact on cycling, mitochondrial content or ROS levels in diverse human cancer cell lines when cultured in 3% FCS
Supplementary Data Figure S4 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S4 showing that removal of mutant TP53 has no impact on survival and proliferation of diverse human cancer cell lines when cultured in 3% FCS
Supplementary Data Figure S28 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S28 showing that removal of mutant TP53 has no impact on the response of tumors derived from human colon cancer derived organoids to 5-FU in vivo
Supplementary Data Figure S27 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S27 showing that removal of mutant TP53 does not impact the in vitro response of human colon cancer derived organoids to cisplatin
Supplementary Data Figure S25 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S25 showing that removal of mutant TP53 has no impact on in vivo tumor growth upon transplantation of human colon cancer derived organoids into NSG mice
Supplementary Data Figure S24 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S24 showing that removal of mutant TP53 does not impair the in vitro growth of human colon cancer derived organoids
Supplementary Data Figure S23 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S23 showing that removal of mutant TRP53 in the E0771 mouse breast cancer cell line has no impact on the tumor microenvironment in vivo
Supplementary Data Figure S22 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S22 showing flow cytometric analysis of the transplanted Eu-Myc mouse lymphoma cells expanding in recipient mice
Supplementary Data Figure S20 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S20 showing that removal of mutant TP53 does not impair the chemotherapy responses of the human colon cancer cell line HT29 in vivo
Supplementary Data Figure S2 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S2 showing that removal of mutant TP53 has no impact on survival, proliferation, mitochondrial content and ROS levels in diverse human cancer cell lines
Supplementary Data Figure S18 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S18 showing that removal of mutant TP53 in SUM159 human breast cancer cells does not impair metastasis in vivo
Supplementary Data Figure S16 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S16 showing that removal of mutant TP53 does not impair in vivo tumor growth of human cancer lines even when limited numbers of cancer cells are transplanted
Supplementary Data Figure S12 from Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells
Authors: Wang Zilu , Burigotto Matteo , Ghetti Sabrina , Vaillant François , Tan Tao , Capaldo Bianca D. , Palmieri Michelle , Hirokawa Yumiko , Tai Lin , Simpson Daniel S. , Chang Catherine , Huang Allan Shuai , Lieschke Elizabeth , Diepstraten Sarah T. , Kaloni Deeksha , Riffkin Chris , Huang David C.S. , Li Wai Suen Connie S.N. , Garnham Alexandra L. , Gibbs Peter , Visvader Jane E. , Sieber Oliver M. , Herold Marco J. , Fava Luca L. , Kelly Gemma L. , Strasser Andreas
Published: February 2024

Supplementary Figure S12 showing that removal of mutant TP53 by RNAi has minor impact on the survival and proliferation of certain human cancer cell lines in culture